➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKinsey
Express Scripts
Boehringer Ingelheim
Merck

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,649,352


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,649,352
Title:High purity oritavancin and method of producing same
Abstract: Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
Inventor(s): Rafai Far; Adel (Mount-Royal, CA), Krishna; Gopal (Parsippany, NJ), Ding; Min (Parsippany, NJ), Chemburkar; Sanjay R. (North Chicago, IL), Knable; Carl M. (North Chicago, IL), Petzel; James P. (North Chicago, IL), Pruyne; Julie J. (North Chicago, IL), Reamer; Douglas M. (North Chicago, IL)
Assignee: THE MEDICINES COMPANY (Parsippany, NJ) ABBVIE INC. (Chicago, IL)
Application Number:14/801,303
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 9,649,352

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta Therap KIMYRSA oritavancin diphosphate POWDER;INTRAVENOUS 214155-001 Mar 12, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;INTRAVENOUS 206334-001 Aug 6, 2014 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,649,352

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015289602 ⤷  Try it Free
Brazil 112017000898 ⤷  Try it Free
Canada 2955256 ⤷  Try it Free
China 107206050 ⤷  Try it Free
Eurasian Patent Organization 201700019 ⤷  Try it Free
European Patent Office 3169345 ⤷  Try it Free
Hong Kong 1244447 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Johnson and Johnson
Express Scripts
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.